Cervical cancer
Conditions
Interventions
Experimental group:The initial treatment regimen was Camrelizumab + TP induction therapy (Camrelizumab on day 1 + Paclitaxel 175 mg/m2 on day 1 + Cisplatin 50 mg/m2 on days 1-3), administered every 3
subsequently, radical simple radiotherapy was performed (with exemption of concurrent cisplatin)
after radiotherapy, Camrelizumab 200 mg was administered every 3 weeks for maintenance treatment, with a total maintenance course of 17 sessions.
Sponsors
Sun Yat-sen University Cancer Center
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Pathologically confirmed cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma. 2. Patients with FIGO 2014 IB2-IIB stage and positive lymph nodes (positive pelvic lymph node biopsy; or >=2 positive pelvic lymph nodes [shortest diameter >= 1.5 cm] detected by MRI or CT, or >=2 positive pelvic lymph nodes [maximum SUV value >= 2.5] detected by PET/CT; or >=1 positive para-aortic lymph node [shortest diameter >= 1.5 cm] detected by MRI or CT, or >=1 positive para-aortic lymph node [maximum SUV value >= 2.5] detected by PET/CT), or FIGO 2014 IIIA-IVA stage with or without positive lymph nodes. 3. No evidence of distant metastasis (M0). 4. Performance status: ECOG score 0-1. 5. Normal bone marrow function: white blood cell count > 4×10^9/L, hemoglobin > 80 g/L (or moderate to severe anemia that can be corrected by blood transfusion), and platelet count > 100×10^9/L. 6. Normal liver function: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 50 mL/min. 8. Patients must be informed of the basic content of this study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with any active, known or suspected autoimmune disease (as listed below, but not limited to interstitial pneumonia, uveitis, enteritis, hepatitis, arthritis, nephritis, pituitary inflammation, hyperthyroidism, hypothyroidism, etc.); the subject has vitiligo; the subject requires bronchodilators for medical intervention for asthma. 2. Age > 70 years or 1.5×ULN), and mental illness. 9. Subjects considered not suitable for inclusion by the investigator. 10. Allergic to any drug in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Distant metastasis-free survival;Locoregional relapse-free survival;Quality of life; | — |
Countries
China
Contacts
Public ContactXinpingCao
Sun Yat-sen University Cancer Center
Outcome results
None listed